U.S. stock market update: Tharimmune up 22.94%

U.S. Stock Market Midday Update Tharimmune rose 22.94%. Based on recent key news: On September 8, Tharimmune Inc. released its latest financial report on the SEC's EDGAR system, showing significant improvement in company performance, driving the stock price up 22.94%. The year-to-date increase reached 69.43%, demonstrating strong market performance. Stocks with High Trading Volume in the Industry Aliram Pharmaceuticals fell 3.39%. According to recent important news: On September 10, Aliram Pharmaceuticals announced the pricing of $575 million in convertible senior notes, raising market concerns about its financial condition, leading to a decline in stock price. On September 9, the company planned to use part of the proceeds to repurchase 1.00% convertible notes maturing in 2027, resulting in mixed market reactions and stock price fluctuations. On September 8, Aliram Pharmaceuticals had an average annual return of 15.62% over the past decade, but recent market performance has been poor, undermining investor confidence. The market's response to the convertible notes has been mixed, increasing volatility. AbbVie fell 0.79%, with increased trading volume. Based on recent key news: On September 9, AbbVie reached a global licensing agreement with Glenmark Pharma, paying $700 million for the exclusive license of ISB 2001. This news boosted Glenmark's stock price but had limited impact on AbbVie's stock price. On September 8, AbbVie's sales of Skyrizi and Rinvoq saw significant growth, although Humira sales declined, the company's overall revenue increased by 8%. This positive financial performance failed to significantly boost the stock price. On September 7, analysts rated AbbVie as "Moderate Buy," but it was not included in the top recommended stocks list, with the market holding a cautious attitude towards its future performance. Increased advertising spending in the pharmaceutical industry has intensified market competition. Travere Therapeutics rose 27.96%. Based on recent important news: On September 10, Travere Therapeutics announced that the FDA no longer requires an advisory committee review for its FILSPARI sNDA application, driving the stock price up. The FDA's PDUFA date is set for January 13, 2026, and the market holds an optimistic outlook on the product's approval prospects. On September 10, Travere Therapeutics' CEO expressed satisfaction with the progress of the sNDA and is prepared to successfully commercialize FILSPARI in January next year, further enhancing investor confidence. On September 10, analysts held a neutral stance on Travere Therapeutics' stock, despite facing financial performance challenges, but technical indicators showed strong buy signals, supporting the stock price increase. The biopharmaceutical industry has performed strongly recently Stocks Ranked Among the Top by Market Capitalization in the Industry Amgen, down 0.84%, with a market capitalization of $149.4 billion and increased trading volume. Based on recent key news: On September 9, Amgen and Kyowa Kirin announced the topline results of the Phase 3 ASCEND long-term extension study of rocatinib monoclonal antibody for adult patients with moderate to severe atopic dermatitis. This news had a positive impact on the stock price but failed to fully offset other negative factors. On September 7, Amgen announced that the final analysis results of the FORTITUDE-101 trial showed reduced survival benefits of bemarituzumab monoclonal antibody in gastric cancer. This news raised market concerns about its prospects, putting pressure on the stock price. On September 10, market analysts maintained a "Hold" rating on Amgen, noting that there are other better investment options. This analyst opinion had a negative impact on the stock price. The pharmaceutical industry performed well overall, but individual stocks experienced significant volatility